Loading video...

Video Failed to Load

There was a problem loading this video. This could be due to a temporary network issue or the video might be unavailable.

Preclinical and observational studies suggest that exercise may improve cancer outcomes. However, definitive level 1 evidence is lacking. The CHALLENGE trial sought to address this knowledge gap. NEJM Editorial Fellow Sarah Gorey, MB (Sarah Gorey), explains in this 60-Second Journal Club video. Read the full trial results:

NEJM

1,033,791 subscribers

12,392 views • 1 year ago •via X (Twitter)

Anya Rossi• Live Now

Private livecam show

2 Comments

Dr. Mahesh Banda1 year ago

@sarah_gorey First step: Case control studies with family history of cancer and age of presentation with physical fitness as one of the major parameter, might determine the next step for the cohort studies.

Naveen Sankar S1 year ago

🚴‍♂️ Higher cardiorespiratory fitness may reduce dementia risk, even for those with a genetic predisposition! A study links high fitness to better cognition and delayed dementia onset by over 1.4 years. 🔗 #DementiaPrevention #Fitness #BrainHealth 🧠

Related Videos

60-Second Journal Club: NEJM Editorial Fellow Sarah Gorey, MB, summarizes the REDOX trial assessing hospitalization and mortality among patients with chronic severe hypoxemia who received long-term oxygen therapy for either 24 or 15 hours per day. Full trial:

60-Second Journal Club: NEJM Editorial Fellow Sarah Gorey, MB, summarizes the REDOX trial assessing hospitalization and mortality among patients with chronic severe hypoxemia who received long-term oxygen therapy for either 24 or 15 hours per day. Full trial:

NEJM

18,799 views • 1 year ago

In this 60-Second Journal Club, NEJM Editorial Fellow Abarna Pearl, MD, MPH, summarizes the BALANCE trial comparing antibiotic treatment for 7 versus 14 days in patients with bloodstream infections. Read the full article and accompanying Research Summary:

In this 60-Second Journal Club, NEJM Editorial Fellow Abarna Pearl, MD, MPH, summarizes the BALANCE trial comparing antibiotic treatment for 7 versus 14 days in patients with bloodstream infections. Read the full article and accompanying Research Summary:

NEJM

10,641 views • 1 year ago

NEJM Editorial Fellow Minali Nigam, MD, shares the key results of the ORIENTAL-MeVO trial, which investigated whether endovascular thrombectomy for acute ischemic stroke improves functional outcomes in patients with medium-vessel occlusion and moderate-to-severe deficits. Read the full trial results:

NEJM Editorial Fellow Minali Nigam, MD, shares the key results of the ORIENTAL-MeVO trial, which investigated whether endovascular thrombectomy for acute ischemic stroke improves functional outcomes in patients with medium-vessel occlusion and moderate-to-severe deficits. Read the full trial results:

NEJM

16,994 views • 1 month ago

Pharmacologic treatment options for cancer cachexia are limited. NEJM Editorial Fellow Harleen Marwah, MD, summarizes research on the safety and efficacy of the monoclonal antibody ponsegromab for treating cancer cachexia. Read the full trial results:

Pharmacologic treatment options for cancer cachexia are limited. NEJM Editorial Fellow Harleen Marwah, MD, summarizes research on the safety and efficacy of the monoclonal antibody ponsegromab for treating cancer cachexia. Read the full trial results:

NEJM

16,522 views • 1 year ago

Observational evidence is conflicting on whether the sex of blood donors affects recipient outcomes. New findings from a randomized trial are summarized in this short video.

Observational evidence is conflicting on whether the sex of blood donors affects recipient outcomes. New findings from a randomized trial are summarized in this short video.

NEJM

42,725 views • 3 years ago

Whole-blood transfusion has recently gained favor in the management of severe hemorrhage, but is it really better than standard care with blood components? NEJM Editorial Fellow Katerina Lin, MD, recaps the results of the SWiFT trial. Read the full trial results:

Whole-blood transfusion has recently gained favor in the management of severe hemorrhage, but is it really better than standard care with blood components? NEJM Editorial Fellow Katerina Lin, MD, recaps the results of the SWiFT trial. Read the full trial results:

NEJM

19,223 views • 29 days ago

What do you counsel patients with #AFib who are candidates for long-term anticoagulation? NEJM Editorial Fellow Katerina Lin, MD, provides an overview of the recently published CHAMPION-AF trial. Read the full trial results:

What do you counsel patients with #AFib who are candidates for long-term anticoagulation? NEJM Editorial Fellow Katerina Lin, MD, provides an overview of the recently published CHAMPION-AF trial. Read the full trial results:

NEJM

34,919 views • 1 month ago

Induction medication for emergency intubation — does the choice matter? NEJM Editorial Fellow Katerina Lin, MD, explains a randomized trial to determine the effects of ketamine vs. etomidate for induction of anesthesia during emergency tracheal intubation. Full RSI trial results:

Induction medication for emergency intubation — does the choice matter? NEJM Editorial Fellow Katerina Lin, MD, explains a randomized trial to determine the effects of ketamine vs. etomidate for induction of anesthesia during emergency tracheal intubation. Full RSI trial results:

NEJM

21,895 views • 5 months ago

This video in our partnership with Dr. Glaucomflecken explains a head-to-head trial comparing rituximab versus ocrelizumab in newly diagnosed relapsing multiple sclerosis. Access the full results of the OVERLORD-MS trial for free: #neurology

This video in our partnership with Dr. Glaucomflecken explains a head-to-head trial comparing rituximab versus ocrelizumab in newly diagnosed relapsing multiple sclerosis. Access the full results of the OVERLORD-MS trial for free: #neurology

NEJM

35,574 views • 1 month ago

Our latest video in our partnership with Dr. Glaucomflecken explains the results of the RESHAPE-HF2 trial investigating whether transcatheter mitral-valve repair improves outcomes in patients with heart failure and functional mitral regurgitation.

Our latest video in our partnership with Dr. Glaucomflecken explains the results of the RESHAPE-HF2 trial investigating whether transcatheter mitral-valve repair improves outcomes in patients with heart failure and functional mitral regurgitation.

NEJM

98,992 views • 1 year ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes a new trial investigating the mass administration of ivermectin for reducing malaria transmission. Read the full results of the BOHEMIA trial for free:

Our latest video in our partnership with Dr. Glaucomflecken summarizes a new trial investigating the mass administration of ivermectin for reducing malaria transmission. Read the full results of the BOHEMIA trial for free:

NEJM

19,398 views • 9 months ago

Monoclonal gammopathy of undetermined significance (MGUS) is a common, asymptomatic plasma-cell disorder in older adults that can progress to cancer or systemic illness. NEJM Editorial Fellow Katerina Lin, MD, shares some key points from a review published in October. Read the full article:

Monoclonal gammopathy of undetermined significance (MGUS) is a common, asymptomatic plasma-cell disorder in older adults that can progress to cancer or systemic illness. NEJM Editorial Fellow Katerina Lin, MD, shares some key points from a review published in October. Read the full article:

NEJM

16,361 views • 7 months ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial investigating the effectiveness of shunt surgery for idiopathic normal-pressure hydrocephalus. Read the full results for free: #neurology

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial investigating the effectiveness of shunt surgery for idiopathic normal-pressure hydrocephalus. Read the full results for free: #neurology

NEJM

56,896 views • 8 months ago

Drs. Greg Katz, MD, Shreya P. Trivedi MD, MHPE & Abby Schubach MD discuss the NordICC trial: Does colonoscopy reduce colorectal cancer incidence? Hear more in the latest episode of Beyond Journal Club, a CORE IM in collaboration with NEJM Group:

Drs. Greg Katz, MD, Shreya P. Trivedi MD, MHPE & Abby Schubach MD discuss the NordICC trial: Does colonoscopy reduce colorectal cancer incidence? Hear more in the latest episode of Beyond Journal Club, a CORE IM in collaboration with NEJM Group:

NEJM

14,595 views • 2 years ago

Ondansetron is often prescribed at ED discharge for children seen for gastroenteritis to reduce further symptoms, but evidence to support doing so is limited. A new trial investigates whether postdischarge ondansetron is beneficial. Full trial results:

Ondansetron is often prescribed at ED discharge for children seen for gastroenteritis to reduce further symptoms, but evidence to support doing so is limited. A new trial investigates whether postdischarge ondansetron is beneficial. Full trial results:

NEJM

14,357 views • 1 year ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial that evaluated whether management of shock without early arterial catheterization is noninferior to the practice of early catheter insertion with regard to death from any cause at day 28. Read the full results for free:

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial that evaluated whether management of shock without early arterial catheterization is noninferior to the practice of early catheter insertion with regard to death from any cause at day 28. Read the full results for free:

NEJM

47,843 views • 8 months ago

In low-risk patients with MI and early complete revascularization, stopping aspirin after 1 month and continuing P2Y12 monotherapy was noninferior to dual antiplatelet therapy for ischemic outcomes and led to reduced bleeding at 1 year. Read the full TARGET-FIRST trial results in the Original Article “Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction”:

In low-risk patients with MI and early complete revascularization, stopping aspirin after 1 month and continuing P2Y12 monotherapy was noninferior to dual antiplatelet therapy for ischemic outcomes and led to reduced bleeding at 1 year. Read the full TARGET-FIRST trial results in the Original Article “Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction”:

NEJM

32,435 views • 9 months ago

Could clesrovimab, a human RSV monoclonal antibody, reduce the incidence of RSV infection in preterm and full-term infants? Find out in the latest video in our partnership with Dr. Glaucomflecken. Read the full results of the CLEVER trial for free:

Could clesrovimab, a human RSV monoclonal antibody, reduce the incidence of RSV infection in preterm and full-term infants? Find out in the latest video in our partnership with Dr. Glaucomflecken. Read the full results of the CLEVER trial for free:

NEJM

46,802 views • 10 months ago